ESMO 2022 Conference Coverage
ESMO 2022 on the SOLO1/GOG-3004 Trial: OS at 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib
By
ESMO 2022 Conference Coverage
FEATURING
Paul DiSilvestro
By
ESMO 2022 Conference Coverage
FEATURING
Paul DiSilvestro
Comments 0
Login to view comments.
Click here to Login
